Vertex Stock News

Manage indirect tax at a single point, leveraged across all your global business units

Your tax department could be using all its data for more than just compliance

A cloud-based solution can improve and automate processes while reducing IT infrastructure and maintenance

Shares of Vertex, Inc. (NASDAQ:VERX) have been assigned a consensus rating of Hold from the nine ratings firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average []

Shares of Vertex, Inc. (NASDAQ:VERX) gapped down prior to trading on Wednesday . The stock had previously closed at $17.39, but opened at $16.84. Vertex shares last traded at $17.07, with a volume of 2,800 shares trading hands. Several equities research analysts have issued reports on VERX shares. William Blair reiterated a buy rating on []

Vertex went public in June 2020, raising $402 million in a U.S. IPO. The firm sells software and services to companies needing a variety of tax calculation and compliance solutions.

KING OF PRUSSIA, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, announced today that its Vertex ® Indirect Tax O Series ® 9.0 solution is certified by SAP as built on SAP Business Technology Platform (SAP BTP), SAP’s platform for the Intelligent Enterprise. The solution has been enhanced to specifically support the tax requirements for companies operating in Brazil.

Wells Fargo & Company began coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research report sent to investors on Wednesday, PriceTargets.com reports. The brokerage issued an overweight rating and a $270.00 price target on the pharmaceutical companys stock. VRTX has been the topic of a number of other research reports. Piper Sandler downgraded Vertex [] The post Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Overweight Rating from Analysts at Wells Fargo & Company appeared first on ETF Daily News .

It''s still early, but a potential cure for the disease isn''t out of the question.

Investors from J.P. Morgan and Vertex and entrepreneurs from Lemonade, JFrog and Verbit discussed startup growth at the Globes Startups Conference.

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- On November 30, 2021, Bloomberg New Energy Finance (BloombergNEF) held the 2021 BloombergNEF Shanghai Summit. Trina Solar Chairman Gao Jifan discussed innova

This article was originally published on TipRanks.com Shares of Vertex Pharmaceuticals Incorporated (VRTX) jumped 9. The post Vertex Reveals Results from Phase 2 Study of VX-147; Shares Jump appeared first on Smarter Analyst .

The company hopes to advance the drug into a pivotal clinical study, following a mid-stage study that showed it reduced excess protein levels.

Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline and was well tolerated Results provide clinical proof of concept for the first genetically targeted approach to treating